Keynote recherche - Guillaume Canaud, From a single patient to an US FDA approved drug...

Item: Keynote recherche - Guillaume Canaud, From a single patient to an US FDA approved drug...
Rating: 5
Author: PostSingularity Institute

by Guillaume Canaud

Life & Natural Systems Medicine & Health MBGRMedical research MBGR1Clinical trials

🎙 Guillaume Canaud 👥 1K 📅 July 20, 2026 ⏱ 83 min 👁 28 📄 original study 🧭 2026-08-16

Available in: English (current) Français

Keywords

PIK3CAalpelisibPROSdrug repurposingcompassionate use

Summary

In this keynote, Professor Guillaume Canaud, a nephrologist at Hôpital Necker and researcher at Inserm, recounts the remarkable story of how a single patient with a rare overgrowth syndrome led to the FDA approval of a repurposed cancer drug. He begins by introducing PIK3CA-related overgrowth spectrum (PROS), a group of mosaic disorders caused by activating mutations in the PIK3CA gene, leading to asymmetric overgrowth of various tissues. The clinical presentations are diverse, ranging from isolated macrodactyly to severe forms like CLOVES syndrome, with complications including bleeding, thrombosis, pain, and organ dysfunction. In 2015, a young patient named Emmanuel presented with severe PROS, heart failure, and renal failure, with a grim prognosis. Canaud, having recently obtained an ERC grant to study the PI3K/AKT/mTOR pathway, recognized the patient’s PIK3CA mutation as a common oncogenic driver. He identified alpelisib, a PI3Kα inhibitor in phase 1 trials for breast cancer, and obtained compassionate use approval from the French health authority. The treatment led to dramatic clinical improvement, with reductions in malformations, heart failure, and pain. This success prompted a prospective clinical trial, leading to FDA approval of alpelisib for PROS in 2022 and European approval in 2024. Canaud emphasizes the importance of translational research, collaboration, and the potential of drug repurposing for rare diseases.

210 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of the information is exceptionally high, providing a detailed, first-hand account of a groundbreaking medical achievement. The argumentation is solid, grounded in clinical observations, molecular biology, and regulatory processes. Canaud systematically explains the scientific rationale, the compassionate use pathway, and the subsequent clinical trial that led to approval. He also transparently discloses conflicts of interest and the role of industry collaboration. The narrative is compelling and well-supported by patient data and imaging.

83 words

Title / Content Match

The title accurately reflects the content: a keynote lecture describing the journey from a single patient to FDA approval of a repurposed drug for a rare disease.

Quality & Reliability

9/10

Presentation by a leading clinician-scientist with extensive publications and awards, detailing a well-documented case of drug repurposing from a single patient to FDA approval. The narrative is supported by clinical data and peer-reviewed research, though it is a single-center experience and not a systematic review.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

Mosaic activating mutations in PIK3CA cause CLOVES syndrome — Identified PIK3CA mutations in CLOVES syndrome
PIK3CA-related overgrowth spectrum (PROS) — Overview of PROS and clinical guidelines
Alpelisib for PIK3CA-Related Overgrowth Spectrum — Clinical trial of alpelisib for PROS leading to FDA approval

Concurring Sources

Mosaic activating mutations in PIK3CA cause CLOVES syndrome — Confirms the genetic basis of PROS
Alpelisib for PIK3CA-Related Overgrowth Spectrum — Clinical trial results supporting efficacy

Contribution & Novelties

This talk provides a unique, personal account of the translational journey from a single patient to a regulatory-approved drug, highlighting the power of drug repurposing and the importance of physician-scientists. It underscores the potential of targeted therapies for rare genetic diseases and the need for adaptive regulatory pathways.

Pour aller plus loin :

PIK3CA gene — Overview of the gene and its role in cancer and overgrowth syndromes.
Alpelisib — Information on the drug and its approved indications.
Compassionate use — Explanation of expanded access programs for investigational drugs.

89 words

Radar Profile

The radar profile shows high scores across all dimensions, indicating a comprehensive and reliable presentation. The talk excels in information quantity and quality, with strong technical depth and high reliability, reflecting the speaker's expertise and the well-documented nature of the case.

Reliability 9/10

💬 Sur les 0 commentaires analysés, aucune tendance n'est disponible.